Corcept Therapeutics (CORT) Financial Analysis & Valuation | Quarter Chart
Corcept Therapeutics (CORT)
CORTPrice: $87.89
Fair Value: 🔒
🔒score
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia s... more
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of... more
Description
Shares
| Market Cap | $9.44B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Joseph K. Belanoff |
| IPO Date | 2004-04-14 | CAGR | — |
| Employees | 500 | Website | www.corcept.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 1.35% | Total Yield | 1.35% |
CORT chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.15B | P/E Ratio | 251.11 |
| Forward P/E | 33.97 | PEG Ratio | — |
| P/S Ratio | 18.09 | P/B Ratio | 21.21 |
| P/CF Ratio | 112.69 | P/FCF Ratio | 116.11 |
| EPS | $0.35 | EPS Growth 1Y | -69.83% |
| EPS Growth 3Y | -57.32% | EPS Growth 5Y | -55.13% |
| Revenue Growth 1Y | 12.2% | Gross Margin | 0.98% |
| Operating Margin | -0.01% | Profit Margin | 0.06% |
| ROE | 0.08% | ROA | 0.06% |
| ROCE | -0.01% | Current Ratio | 2.86 |
| Quick Ratio | 2.77 | Cash Ratio | 0.73 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 34.59 | Piotroski Score | 5 |